NeoGenomics, Inc. (NASDAQ:NEO) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Jeff Sherman - Chief Financial Officer Warren Stone - President of Clinical Service Division Vishal Sikri - President of Advanced Diagnostics Division Melody Harris - President of Enterprise Operations Conference Call Participants Alex Nowak - Craig-Hallum Mark Massaro - BTIG Andrew Brackmann - William Blair Puneet Souda - SVB Securities Tejas Savant - Morga ...

Sequential Improvement in Revenue Growth, • Adjusted EBITDA. Improved $8.6 million versus prior year due to improvement in gross profit and lower operating expenses. Balance Sheet In $Millions Dec-22 Sep-22 Total Assets 1,740.0 1,755.6 Accounts payable and other current liabilities 83.3 78.5 Current portion of equipment financing obligations 0.1 0.1 Current portion of operating lease liabilities 6.6 6.4 Total stockholders' equity 998.0 1,013.0 • Financial Flexibility to Make Needed Investments to Drive Long ...

Saving lives by improving patient care. 3 rd Quarter 2022 Earnings Results November 8th, 2022 1 2 Forward looking statement This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to r ...

NeoGenomics, Inc. (NASDAQ:NEO) Q3 2022 Results Conference Call November 8, 2022 8:30 AM ET Company Participants Chris Smith - Chief Executive Officer Bill Bonello - Chief Financial Officer Vishal Sikri - President of our Pharma Services Division, Inivata Shashi Kulkarni - President of Lab Operations and CSO Conference Call Participants Alex Nowak - Craig-Hallam Capital Andrew Brackmann - William Blair David Delahunt - Goldman Sachs Puneet Souda - SVB Securities Andrew Cooper - Raymond James Mark Massaro - B ...

| --- | --- | --- | --- | --- | --- | |-----------------------------------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | | August 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer t ...

NeoGenomics, Inc. (NASDAQ:NEO) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Lynn Tetrault ??? Interim CEO Charlie Eidson ??? Director of Investor Relations Bill Bonello ??? Chief Financial Officer Chris Smith ??? Incoming Chief Executive Officer David Sholehvar ??? President, Clinical Division Vishal Sikri ??? President, Pharma Services Division and President-Inivata Conference Call Participants Brian Weinstein ??? William Blair Alex Nowak ??? Craig-Hallum David Westenberg ...

NeoGenomics, Inc. (NASDAQ:NEO) Q1 2022 Earnings Conference Call April 27, 2022 8:30 AM ET Company Participants Lynn Tetrault - Executive Chair & Principal Executive Officer William Bonello - Chief Financial Officer Doug Brown - Chief Strategy and Corporate Development Officer Charlie Eidson - Director, Investor Relations Shashi Kulkarni - Chief Scientific Officer David Sholehvar - Clinical Division President Conference Call Participants Brian Weinstein - William Blair Matt Sykes - Goldman Sachs Andrew Coope ...

| --- | --- | --- | --- | --- | --- | |-----------------------|-------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Investor Presentation | NeoGenomics | | | | | | April 2022 | | | | | | Forward-Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy s ...

| --- | --- | --- | --- | --- | |-------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | NeoGenomics Investor Presentation | | | | | | February 2022 | | | | | Forward‐Looking Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company") and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of ...

NeoGenomics Inc. (NASDAQ:NEO) Q4 2021 Earnings Conference Call February 23, 2022 8:30 AM ET Company Participants Mark Mallon - Chief Executive Officer William Bonello - Chief Financial Officer Clive Morris - President, Inivata George Cardoza - President, Chief Operating Officer Gina Waller - President, Pharma Services Clynt Taylor - President, Informatics Charlie Eidson - Director, Investor Relations Conference Call Participants Brian Weinstein - William Blair Mark Massaro - BTIG Alex Nowak - Craig Hallum P ...